EU CHMP Recommends Approval Of Daiichi Sankyo and AstraZeneca's Datroway For First-Line Treatment Of Adult Patients With Unresectable Or Metastatic Triple Negative Breast Cancer

Loading news article.

EU CHMP Recommends Approval Of Daiichi Sankyo and AstraZeneca's Datroway For First-Line Treatment Of Adult Patients With Unresectable Or Metastatic Triple Negative Breast Cancer | WAPE

EU CHMP Recommends Approval Of Daiichi Sankyo and AstraZeneca's Datroway For First-Line Treatment Of Adult Patients With Unresectable Or Metastatic Triple Negative Breast Cancer

Article summary

Related companies

Comments —